The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. - Wikidata - wikimedia - TriplyDB

The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.

The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.

http://www.wikidata.org/entity/Q30547123

about

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options The translational study of apathy-an ecological approach Motivational Deficits in Schizophrenia and the Representation of Expected Value The current conceptualization of negative symptoms in schizophrenia Vocal expression in schizophrenia: Less than meets the ear.What do we really know about blunted vocal affect and alogia? A meta-analysis of objective assessments.Automated computerized analysis of speech in psychiatric disorders.Effectiveness of one-to-one volunteer support for patients with psychosis: protocol of a randomised controlled trial.Using video-annotation software to identify interactions in group therapies for schizophrenia: assessing reliability and associations with outcomes.The impact of gender on treatment effectiveness of body psychotherapy for negative symptoms of schizophrenia: A secondary analysis of the NESS trial data.Natural language processing to extract symptoms of severe mental illness from clinical text: the Clinical Record Interactive Search Comprehensive Data Extraction (CRIS-CODE) project.The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs.Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study Characterization of psychotic experiences in adolescence using the specific psychotic experiences questionnaire: findings from a study of 5000 16-year-old twins.Negative symptoms in schizophrenia.Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions.Oxytocin-augmented social cognitive skills training in schizophrenia.Brain structural signatures of negative symptoms in depression and schizophrenia Subthreshold psychotic symptoms in 22q11.2 deletion syndrome.Behavioral approach and avoidance in schizophrenia: an evaluation of motivational profiles.Deficits in anticipatory but not consummatory pleasure in people with recent-onset schizophrenia spectrum disorders.Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures.Validation of the Chinese version of the Clinical Assessment Interview for Negative Symptoms (CAINS): a preliminary report.Unseen Affective Faces Influence Person Perception Judgments in Schizophrenia.Perceived emotional intelligence is impaired and associated with poor community functioning in schizophrenia and bipolar disorder.Neurodevelopmental and environmental hypotheses of negative symptoms of schizophrenia TextHunter--A User Friendly Tool for Extracting Generic Concepts from Free Text in Clinical Research.Instruments measuring blunted affect in schizophrenia: a systematic review Negative symptoms in youths with psychosis spectrum features: complementary scales in relation to neurocognitive performance and function.Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder.Confirmatory Factor Analysis and Differential Relationships of the Two Subdomains of Negative Symptoms in Chronically Ill Psychotic Patients.White matter alterations in first episode treatment-naïve patients with deficit schizophrenia: a combined VBM and DTI study.RETRACTED: Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 2—External Validity and Correlates.Examining associations between psychosis risk, social anhedonia, and performance of striatum-related behavioral tasks.Mindfulness in schizophrenia: Associations with self-reported motivation, emotion regulation, dysfunctional attitudes, and negative symptoms N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms.Modeling the role of negative symptoms in determining social functioning in individuals at clinical high risk of psychosis.Inefficient effort allocation and negative symptoms in individuals with schizophrenia.Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System.

P2860

Q22241447-AD35361F-4D00-4262-9361-3B3736BA8E68 Q26781597-75549AE1-9375-48C8-A92B-2A5D3D7FAFAE Q26786992-565C578A-0A67-4D17-8211-25820F23E36D Q30364829-6CB27F05-0D7A-4DE0-B322-635DB99D7D7D Q30378034-139144CE-7E5B-4E2B-8BD3-B65BE7A83CC8 Q30400036-F688622B-B725-42F6-8640-FA5F3D7CA4BE Q30412969-1DD6ADA6-43F2-4A17-B732-512185313B81 Q30489653-A28FB164-70C2-4395-84D3-5DD0CD26137A Q30838181-5DAB6310-1817-499E-8D0B-4BCDEE52AD88 Q31143748-95F76012-870F-4DF6-B0AB-0B25E9C700B1 Q31155106-787138E2-324E-429E-BFBE-51DC4CF3E943 Q33610776-966E00C5-0579-46EC-8720-E491A932744B Q33635522-39408284-3F65-4067-AD7A-48CD00EB6DCC Q33762519-1B10733F-1346-4692-8022-2CC78CFFEE02 Q33820512-69C4E013-9506-4FCF-A344-5F11BF49416D Q33882729-7C50FF08-91F6-4BD8-A383-7F41A17A6F58 Q33923629-6BE1FC2E-F664-4BFA-B693-240A7171C1A9 Q34093633-8F2A790C-D440-46CD-939E-5ED623FEEABA Q34156406-8213B072-19F0-48C6-AEB9-E33DC3BCB82B Q34254314-78B75C55-EDCA-41EB-A071-4F1287798BB0 Q34254412-C3CE7419-A7D0-4527-8263-07D513133D91 Q34322992-9ED4A2C3-5B0B-4081-912D-9C95E6229117 Q35037228-0FB06A0C-F2B4-4DA7-B498-1969E737D9AE Q35046702-632E11CA-73E0-43B8-8008-D15BF2B4BCB5 Q35118249-AAE413A4-6F52-4519-BB7F-9458C424855D Q35131870-9226CCEE-3232-4C5C-9D3F-78C7814713EE Q35570517-FEBC4211-77B0-4731-A59D-7BE8EDAD7120 Q35649715-9615618F-325C-410F-B08D-6E347C854D86 Q35883039-B0EA5E6A-B736-4171-ABD1-89102B1E5292 Q35892303-29D639AE-89B5-4E6A-9267-65B6B4D853F9 Q35928639-DD020A37-AA3B-400D-8DBD-458E0D24EDD2 Q35932602-0D2E2E70-4245-4E67-8E99-2B8840A11859 Q35940721-CD5CBA58-BC8B-4BBE-BF5C-D783E72422D7 Q35950856-923E54A7-2892-4D1F-A82D-9D72D6F59A79 Q36070250-856D3C5C-26CD-4579-B97C-4AE24B282532 Q36113606-EFA89BF3-000C-4797-8BC5-9EF76C37EC5A Q36133400-C1E87369-7BC5-4005-96EA-CCBEB3A01E98 Q36378238-B49EAB86-9D19-4C8D-A4C5-E720B5665511 Q36540506-19B6DE87-BDE7-4E15-98BD-FC41E9BBBD6E Q36594933-048DDE10-6956-424D-A40A-DAF124BFF183

P2860

The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.

http://www.wikidata.org/entity/Q30547123

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The Clinical Assessment Interv ...... al development and validation.

@ast

The Clinical Assessment Interv ...... al development and validation.

@en

type

label

The Clinical Assessment Interv ...... al development and validation.

@ast

The Clinical Assessment Interv ...... al development and validation.

@en

prefLabel

The Clinical Assessment Interv ...... al development and validation.

@ast

The Clinical Assessment Interv ...... al development and validation.

@en

P1433

Q30547123-7DAFAB57-38F9-41F3-A895-EA3032FC6ACE

P1476

Q30547123-13AE050F-26C0-4145-929B-59DBE1C394A6

P2093

Q30547123-80D356EF-C84A-4657-8211-59BB637C346B

Q30547123-AF09BA0B-B610-43CB-A0C6-88199AF591E0

Q30547123-E7A107F1-0D7B-4C04-A99B-5DC90F7E2F45

Q30547123-F47498CB-3A89-4736-932A-98D26FA3C238

P2860

Q30547123-0702C29B-5417-446F-9789-A26E2EBBA5BF

Q30547123-1E280985-5530-4930-A337-8E77B8B2BF69

Q30547123-2B8287F1-C756-4E0D-8FBF-B42E4E6C4A2D

Q30547123-2D08DDF8-403F-4A72-9CAD-6EA99F1A5ECF

Q30547123-2F45FBC1-7434-4CF3-AA81-1CD72C43D209

Q30547123-2F5D5E77-B5DE-4E2A-8532-8CCF5D3DAEE0

Q30547123-3C855A71-7F12-4FCC-92ED-4846553A3A6C

Q30547123-3FBA30F5-F741-4D35-B18E-955F85E24B20

Q30547123-4662ACBC-77F9-4EE2-99A1-152968B400B0

Q30547123-476C2970-F115-4B2F-8BB0-253D1B4DAAD8

P304

Q30547123-EFFBC289-6655-4B61-A984-8EBBB636536E

P31

Q30547123-FDCB9C60-B89B-4EF2-B4DA-0D198C69C42F

P356

Q30547123-73030D3F-795F-4367-850C-F7BF57EDB8B5

P407

Q30547123-C33638F5-44A7-467C-B552-D20C47B12492

P433

Q30547123-87CB0D1C-4226-44BA-8AD4-435A93F1092A

P478

Q30547123-EED62E67-8F15-426F-90F5-EB54ECF49366

P50

Q30547123-81057555-2456-4262-90E1-71067C5A65BA

P577

Q30547123-C4E26B6A-7B62-4BF3-A7CC-EDCBB724D645

P5875

Q30547123-9930CDE9-8891-4BAA-B754-D5430E6D8CC5

P698

Q30547123-E471668F-A3D5-4DBF-9AEE-5098E7AC9820

P932

Q30547123-C48EAA30-3902-4C9C-AAE4-0F0A1903811C

P356

APPI.AJP.2012.12010109

P1433

American Journal of Psychiatry

P1476

The Clinical Assessment Interv ...... al development and validation.

@en

P2093

Ann M Kring

http://www.w3.org/2001/XMLSchema#string

Jack J Blanchard

http://www.w3.org/2001/XMLSchema#string

Steven P Reise

http://www.w3.org/2001/XMLSchema#string

William P Horan

http://www.w3.org/2001/XMLSchema#string

P2860

Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures

The neurobiology of anhedonia and other reward-related deficits

Intraclass correlations: uses in assessing rater reliability

The positive and negative syndrome scale (PANSS) for schizophrenia

Research domain criteria (RDoC): toward a new classification framework for research on mental disorders

Patterns of emotional experience in schizophrenia: differences in emotional response to visual stimuli are associated with clinical presentation and functional outcome.

Anhedonia in schizophrenia: a review of assessment strategies

Negative symptoms and cognitive deficits: what is the nature of their relationship?

Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis

P304

165-172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1176/APPI.AJP.2012.12010109

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262042114

http://www.w3.org/2001/XMLSchema#string

P698

23377637

http://www.w3.org/2001/XMLSchema#string

P932

3785242

http://www.w3.org/2001/XMLSchema#string